Clinical Trials Logo

Coronary Occlusions clinical trials

View clinical trials related to Coronary Occlusions.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01012869 Completed - Coronary Occlusions Clinical Trials

AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study

ACE-CTO
Start date: November 2009
Phase: Phase 4
Study type: Interventional

Chronically total occlusions (CTO) are difficult to treat and have high risk for restenosis. Although everolimus-eluting stents (EES) [(Xience, Abbott Vascular) or Promus (Boston Scientific)] are very promising for the treatment of CTOs due to their low late loss and excellent deliverability, there are currently no published data on EES implantation in CTOs. The specific aim of this proposal is to examine the 8-month incidence of binary angiographic in-stent restenosis (defined as a stenosis of > 50% of the minimum lumen diameter of the target stent) after implantation of the EES in CTO. It is the investigators hypothesis that EES-treated CTO lesions will have ≤ 20% 8-month in-stent binary angiographic restenosis rate.

NCT ID: NCT00378612 Completed - Coronary Occlusions Clinical Trials

ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial

Start date: June 2005
Phase: Phase 3
Study type: Interventional

ACROSS-Cypher® is a prospective, multi-center, open label, single arm study of the Cypher® sirolimus eluting coronary stent in native total coronary occlusion revascularization. The primary endpoint is binary angiographic restenosis at 6 months. The TOSCA-1 trial will be used as the historical control. The hypothesis is that compared with TOSCA-1 patients who were treated with the heparin-coated Palmaz Schatz stent, treatment with the Cypher® sirolimus eluting coronary stent will result in a >50% relative reduction in 6 month restenosis within the treated segment of the target vessel.